Vendor Intelligence Report: Astro Peptides

Published 3 Jul 2026. 25-page investigative report on who is behind Astro Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 29 Finnrick lab tests, Astro Peptides records 10 passes and 19 failures for a 34% overall pass rate. The record is not evenly bad: Ipamorelin and Semaglutide are the comparatively defensible lanes, while CJC-1295 and BPC-157 carry the hard warning, with both failing throughout the current Finnrick corpus. Ratings also move under stricter Finnrick scoring, so even the better side still needs current lot-specific verification.

Operational risk is not theoretical. Trustpilot and Reddit evidence show a polarized vendor: many orders appear to complete, but the severe tail repeats the same pattern — payment sent, order on hold, stale Zelle or payment-matching confusion, delayed tracking, and weak follow-up. That matters because the reviewed checkout path relies on Venmo/Zelle-style rails rather than a documented credit-card dispute route.

The identity trail is thinner than the storefront suggests. Astro presents as a US RUO peptide shop, yet the report did not verify a matching Astro Peptides or Astro LLC registration in the searched Delaware records, did not surface named personnel, and ties the payment identity to a Venmo Business handle rather than a clean public entity trail.

The strongest ownership signal is technical, not biographical: shared SPF mail infrastructure, a niche WordPress plugin fingerprint, related phone-number clues, and payment evidence connect Astro with Optima Supply and Hydro Research Peptides. The result is a brand-switching warning — leaving Astro for a sister-looking storefront may not leave the underlying operating cluster.

Inside the full report:

  • Per-product pass/fail rates, trajectories, and methodology-divergence charts for all four tested products
  • RDAP, Wayback, and Delaware registry exhibits anchoring the 2023 launch and unresolved entity trail
  • Shared-infrastructure analysis across Astro, Optima Supply, and Hydro Research Peptides
  • Payment-rail review covering Venmo @AstroLLC, Zelle, and buyer-recovery exposure
  • Trustpilot and Reddit complaint corpus on order holds, wrong orders, and support failures
  • Storefront-change review covering ASTRO-S, ASTRO-R, discount codes, and COA/endotoxin claims

Risk assessment

  • CJC-1295 quality risk — high: CJC-1295: 8 Finnrick tests, 0 pass / 8 fail; current rating 14.74%; avoid absent lot-specific verification.
  • BPC-157 quality risk — high: BPC-157: 7 Finnrick tests, 0 pass / 7 fail; current rating 32.89%; avoid absent lot-specific verification.
  • Fulfillment and customer-service risk — high: Trustpilot 3.0/5 across 173 reviews; polarized distribution and 2026 complaints document delays, order holds, and poor response.
  • Payment-recovery risk — high: Venmo/Zelle routing; no clear credit-card dispute path documented; risk of irrecoverable funds if an order remains on hold.
  • Corporate-transparency and multi-brand-confusion risk — medium: No verified Astro entity/address/personnel; DNS, plugin, phone, and payment clues link Astro to Optima/Hydro multi-brand cluster.